6
February 2024
MicroSalt
Plc
("MicroSalt" or the "Company")
Strategy
Objectives
MicroSalt plc (AIM:SALT), a company
commercialising a patented technology to produce full-flavour,
low-sodium salt for food manufacturers and consumers, is delighted
to announce its first strategy objectives as a London-listed
company.
Strategy Highlights:
·
MicroSalt is sufficiently capitalised and
well-positioned to pursue immediate opportunities in its business
to business ("B2B") and business to consumer ("B2C")
channels.
·
The Board believe nearer term profitable growth
will primarily be driven by its B2B business. In 2024, the Company
will continue to prioritise conversion of current B2B customer
trials into commercial volume orders, expanding current product
line sales across to other product lines and to establish new
potential B2B partners to reformulate their product ingredients
using MicroSalt technology to reduce sodium content.
·
Having secured commercial orders from Customer B,
the Mexican business of one of the world's largest food, soft drink
and snack manufacturers, and Customer A, a national Fortune-500
pharmacy / food retailer, for use in their crisp and salted nuts
lines, the Board see a clear path to sales growth in its higher
volume B2B business. The Company expects to announce new orders and
new customers, primarily based in the US, in the coming
period.
·
MicroSalt is in early-stage discussions with three
of the largest UK supermarkets to use MicroSalt technology in their
own-label products, as well as suppliers of ready-meals and a fast
food burger company.
·
MicroSalt plans to attend at least 12 food shows
globally, including international events in Frankfurt, Paris,
Shanghai, Dubai, and Stockholm.
·
In addition to over 1,000 US and Filipino outlets
stocking MicroSalt salt shakers, the Company will maintain its
global expansion, aiming to make B2C products available in more
top-tier retail stores, and in new territories.
·
To manage expected growing order volumes, the
Company will continuously monitor and expand as appropriate its
global distribution and logistics network of third party
manufacturing facilities, storage hubs, and transportation routes.
In the longer term, the Board may determine it appropriate to build
and manufacture some of its required volumes inhouse.
·
The Company is encouraged by global regulatory
agendas supporting reduced sodium consumption and will seek to
engage constructively with authorities and policymakers.
·
Through MicroSalt's marketing and sales strategy,
the Company will continue to educate consumers on the health
benefits of lowering sodium consumption, and communicate to the
food manufacturing industry the commercial benefits of
reformulating products with MicroSalt's low sodium
technology.
Reformulation
MicroSalt is working with existing
and potential customers to reformulate products in order to reduce
sodium content using MicroSalt's patented technology. The Company
is encouraged by results to date, which include successful testing
results for Customers A, B and C (as described in the Company's
admission document). MicroSalt has a sales pipeline of potential
customers engaged in testing and expects to announce additional
updates throughout 2024.
MicroSalt has proved its technology
can be implemented in the reformulation of ingredients of crisps,
bread, ready meals, and coatings for salted nuts. The Company
believes many more products have the potential to include MicroSalt
technology.
The Company believes a substantial
commercial opportunity exists through the changing attitudes of
major food companies to reduce sodium, and that it is well
positioned to take advantage of the nascent market for a healthier
alternative that tastes like traditional salt.
Sodium Reduction Market
In 2021, the global sodium reduction
ingredients market was estimated to be US$5.5 billion, with the
expectation that it will reach US$9.6 billion by 2032, a compound
annual growth rate of 5.8%.
Excess sodium consumption is a
leading global health problem and consumers are looking to
healthier salt alternatives. 86 per cent of US healthcare costs are
related to chronic diseases, and cardiovascular disease plays a
prominent role. The World Health Organisation ("WHO") has set a
target of reducing global sodium intake by 30% by 2025, which it
estimates will save 7 million lives by 2030. WHO research also
found that every US$1 spent on sodium reduction translates to US$12
in healthcare cost savings for treating cardiovascular
disease1.
The Havard Medical School reviewed
research (JAMA, 11 November 2023) suggesting that reducing salt
intake by one teaspoon per day will have the same impact on blood
pressure as taking medication2.
1https://www.who.int/news-room/fact-sheets/detail/salt-reduction
2https://www.health.harvard.edu/heart-health/cutting-sodium-significantly-lowers-blood-pressure
Defined terms used in this
announcement shall have the same meaning as those defined in the
Company's admission document dated 27 January 2024.
For
more information, please visit MicroSalt's
website, follow on
Twitter @MicroSaltPLC
or
contact:
MicroSalt plc
|
Via Flagstaff PR
|
Rick Guiney, CEO
|
|
|
|
Zeus (Nominated Adviser and
Broker)
|
+44 (0)20 3829 5000
|
David Foreman / James Edis
(Investment Banking)
|
|
Dom King (Corporate Broking), Rupert
Woolfenden (Sales)
|
|
|
|
Flagstaff PR (Financial
PR/IR)
|
+44 (0)20 7129 1474
|
Tim Thompson / Alison Allfrey / Anna
Probert
|
microsalt@flagstaffcomms.com
|
Redchurch Communications (Media
Relations)
|
microsalt@weareredchurch.com
|
Jonathan Roy / John Casey
|
|
Notes to Editors
MicroSalt® produces a patented
full-flavour, low-sodium salt for food manufacturers and
consumers.
MicroSalt is a major potential
disruptor in the food market, thanks to its micron sized particles
which deliver the same sense of saltiness to a wide range of foods
but with approximately 50% less sodium. Excess sodium consumption
is a significant contributor to cardiovascular disease and
MicroSalt's solution meets the rising demand for healthier
alternatives to traditional salt. The WHO
has set a target for reducing global sodium intake by 30% by 2025,
which it estimates will save 7 million lives by 2030.
Each year, cardiovascular disease
costs the UK £19 billion - if the average salt intake was reduced
by one gram per day, it has been estimated that 4,147 lives and
£288 million would be saved each year in the UK. As a nation, the
UK consumes 183 million kilograms of salt each year, and 70 per
cent. of the typical person's sodium intake is hidden in processed
foods.
Operational since 2018, MicroSalt
uses a patent-protected technology which helps create high barriers
to entry within the reduced-sodium salt market. The group has a US
patent and 14 patent applications pending in other jurisdictions
globally.
The Directors believe that MicroSalt
is well positioned to capture growth in the low sodium market,
which is expected to grow exponentially, and that there is also
scope to enter the larger salt market.
MicroSalt has a three-pronged
marketing strategy, targeting large B2B food manufacturers, the B2C
market and e-commerce customers. Microsalt's all natural,
low-sodium solution is well positioned to take advantage of the
fast-growing market for a healthier alternative to traditional
salt.
ENDS